NCT04655911View on ClinicalTrials.gov

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

TerminatedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions
Mucopolysaccharidosis III-B
Interventions
BIOLOGICAL

ABO-101

Gene therapy rAAV9.CMV.hNAGLU

Trial Locations (3)

20246

University Hospital Hamburg-Eppendorf, Hamburg

43205

Nationwide Children's Hospital, Columbus

75571

Armand-Trousseau Hospital, Paris

Sponsors
All Listed Sponsors
lead

Abeona Therapeutics, Inc

INDUSTRY

NCT04655911 - A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101 | Biotech Hunter | Biotech Hunter